Blocking TLR1/2 signaling significantly reduced the therapeutic efficacy of the immunogenic chemotherapeutic agent, resulting in reduced infiltration of DCs, CD4, and CD8 within the tumor microenvironment. This evidence concerns the gene TLR1 and neoplasm.